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Abstract
Background: The growing need for functional studies of genes has set the stage for the development of versatile
tools for genetic manipulations.
Results: Aiming to provide tools for high throughput analysis of gene functions, we have developed a modified
short hairpin RNA (shRNA) and gene expression system based on Gateway Technology. The system contains a
series of entry and destination vectors that enables easy transfer of shRNA or cDNA into lentiviral expression
systems with a variety of selection or marker genes (i.e. puromycin, hygromycin, green fluorescent protein-EGFP,
yellow fluorescent protein-YFP and red fluorescent protein-dsRed2). Our shRNA entry vector pENTR.hU6.hH1
containing two tandem human shRNA expression promoters, H1 and U6, was capable of co-expressing two shRNA
sequences simultaneously. The entry vector for gene overexpression, pENTR.CMV.ON was constructed to contain
CMV promoter with a multiple cloning site flanked by loxP sites allowing for subsequent Cre/lox recombination.
Both shRNA and cDNA expression vectors also contained attL sites necessary for recombination with attR sites in
our destination expression vectors. As proof of principle we demonstrate the functionality and efficiency of this
system by testing expression of several cDNA and shRNA sequences in a number of cell lines.
Conclusion: Our system is a valuable addition to already existing library of Gateway based vectors and can be an
essential tool for many aspects of gene functional studies.
Background
In the era of whole genome sequencing and proteomics,
there has never been a greater need to develop versatile
tools for gene functional studies. Such studies necessi-
tate a series of genetic manipulations including overex-
pression and/or downregulation of genes of interest
either in in vivo and/or in vitro settings. Downregulation
of genes has been made possible by RNA interference
(RNAi) technology [1] and targeting genes using
expressed short hairpin RNA [2,3] is currently the
method of choice by a majority of researchers. The
most successful RNAi libraries based on retroviral [4]
and lentiviral expression [5,6] of shRNAs have also been
utilized for large-scale functional genomic screens [6].
Many gene expression platforms have been developed
over years that allow for the constitutive or inducible
expression of genes/shRNAs [2,3]. Furthermore, several
systems for the downregulation or overexpression of
multiple targets have been adapted to address issues
such as isoform redundancy, endogenous mutations of
single shRNAs and successful targeting of signaling
pathways [7-19].
Expression platforms have been constructed either
using classical restriction-enzyme based cloning technol-
ogy or novel recombination based technologies, of
which the Gateway technology has gained an unprece-
dented use. Gateway utilizes elements of site-specific
recombination of Escherichia coli bacteriophage lambda
integrase/att to enable the transfer of genes between dif-
ferent vectors [20,21]. While many varieties of Gateway-
compatible vectors are available, problems may be
encountered when either additional markers and/or dif-
ferent expression platforms are needed. This is especially
the case for in vitro transformation experiments that are
designed to introduce multiple genetic aberrations to
cell lines in a stepwise fashion.
To enable efficient transfer of genes/shRNAs through
different expression platforms, we have combined
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cloning technology and designed two entry vectors for
either double shRNA or Cre/lox inducible gene expres-
sion and a series of lentiviral destination vectors con-
taining an array of markers. We took advantage of
already available and widely used expression/shRNA
vectors to facilitate the conversion of reagents from one
platform to the other. We have generated an additional,
fully compatible system with currently available Gateway
vectors which should further facilitate gene functional
studies.
Results and discussion
Design of modified Gateway shRNA/gene expression
system
We utilized a combination of restriction-based cloning
and highly versatile Gateway site-directed recombina-
tion technology for the construction of modified
gene/shRNA expression system. This system consists
of two main components: gene/shRNA entry and len-
tiviral destination vectors (Figure 1). Shuffling of
inserts from entry vectors to any of lentiviral destina-
tion vectors is mediated by LR recombination reac-
tion. Cloning details are provided in the Materials and
Methods.
T h ed o u b l es h R N Ae n t r yv e c t o r ,p E N T R . h U 6 . h H 1 ,
was designed by combining shRNA promoter cassettes
from two published shRNA expression vectors, pSUPER.
retro and plko.1.puro. One advantage of this strategy is
the availability of shRNA cassettes based on the sub-
cloning into pSUPER.retro or plko.1.puro. These cas-
settes are used for construction of the most extensively
used shRNA libraries [4,5]. While these libraries have
been applied successfully over the last 5 years, one of
their major limitations is the extent of available selection
markers. This is often the case in cell lines that require
Figure 1 Schematic diagram of shRNA/cDNA lentiviral expression platform. This system consists of two entry vectors, pENTR.hU6.hH1 and
pENTR.CMV.ON and six lentiviral destination vectors containing different selection markers. Entry vector insert is flanked by attL sites used for
recombination with attR sites found in the lentiviral destination vectors. C/LTR, fusion between the CMV IE gene enhancer and the promoter of
the HIV 5’/LTR; ψ, RNA packaging signal; hPGK, human phosphoglycerate kinase eukaryotic promoter; CMV, cytomegalovirus promoter; SV40,
simian-virus 40 promoter, puro, puromycin resistance gene; hygro, hygromycin resistance gene;; YFP, yellow fluorescent protein; EGFP, enhanced
green fluorescent protein; dsRed2, red fluorescent protein; SIN/LTR,3 ’ self inactivating long terminal repeat; RRE, Rev response element; WPRE,
600-bp post-transcriptional regulatory element from Woodchuck hepatitis virus.
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Therefore, subcloning of shRNA libraries in a more ver-
satile vector that allows for downstream transfer of
shRNA cassettes to various expression platforms is
highly desirable. Hence, the construction of pENTR.
hU6.hH1 would allow for easy transfer of subcloned
shRNA cassettes to different gateway based expression
vectors, shRNA targeting of multiple genes, and the
increased knockdown of a single target using multiple
shRNA sequences. Furthermore, since pENTR.hU6.hH1
vector contains two different shRNA expression promo-
ters, this would possibly prevent subsequent endogenous
recombinations known to occur in shRNA vectors with
the same tandem promoters [16].
Gene expression vector pENTR.CMV.ON is based on
Cre/lox recombination and contains CMV promoter
and MCS flanked by loxP sites. Most of the entry vec-
tors available to date are promoterless and are recom-
bined in promoter containing expression vectors. In
addition, subcloning into these vectors can be accom-
plished by attB-PCR recombination avoiding restriction-
based cloning. While these vectors have been extensively
u s e d ,t h e ym i g h tn o tb ea d e q u a t ef o rc e r t a i na p p l i c a -
tions. For example, attB-PCR requires very long primer
sequences which sometimes results in labor intensive
and time consuming PCR troubleshooting especially
during amplifications of large DNA fragments. This
might inadvertently increase a chance of possible trans-
gene mutations arising during the PCR reaction. Hence,
researchers would still have to resort to a more accurate
restriction enzyme-based cloning. Furthermore, gene
functional studies very frequently require the inducible
transgene expression. To this end, we incorporated Cre/
LOX technology to our gene expression platform. The
final entry vector, pENTR.CMV.ON (Figure 1), contains
a potent CMV promoter which provides a better chance
of gene overexpression as well as loxP sites required for
Cre recombinase excision. To our knowledge, this is the
first entry vector available for Cre/lox based gene
expression.
The destination vectors constructed in this study
(Figure 1) are based on the lentiviral gene expression
which is the most utilized system to efficiently transduce
hard to transfect cell lines or primary mammalian cells.
Our destination vectors were engineered to express an
array of selection markers through transgene indepen-
dent promoters. While our system was under construc-
tion, two additional versatile Gateway based expression
systems were reported [19,22]. Zhu et al. [19] con-
structed bicistronic lentiviral gateway destination vectors
with internal-ribosome entry site (IRES) which co-
express the miR-shRNA with a variety of selection mar-
kers. While IRES has many advantages for the co-
expression of transgenes, there have been some major
limitations reported regarding their use. Several reports
have shown that the IRES level of transgene expression
depended considerably on the type of targeted cell
[23,24]. Additionally, it was shown that IRES dependent
translation could be affected by the first cistron with
certain cistrons having inhibitory activity on IRES
through yet undefined mechanisms [24,25]. Martin et al.
[26] have also reported that several commercially avail-
able bicistronic vectors based on the IRES from Ence-
phalomyocarditis virus (EMCV) have the 11
th AUG
modified to a HindIII site to allow for easier subcloning
[26]. However, this modification decreases dramatically
the expression of the IRES-controlled coding sequence.
Thus, our collection of lentiviral destination vectors will
provide an alternative option to researchers faced with
low level expression of the IRES-controlled transgene.
Campeau et al. have similarly developed an extensive
array of lentiviral destination vectors [22] including pro-
moterless pLentiX1 series which are compatible with
our entry vectors. However, in this work we have con-
structed additional destination vectors expressing YFP,
hygro and dsRed2 markers.
Functionality of shRNA double promoter expression
entry vector
To demonstrate the efficacy of pENTR.hU6.hH1 con-
struct we assessed its silencing effect on single and mul-
tiple gene targets. To test the functionality of both hU6
and hH1 promoters, we created three double promoter
shRNA expression vectors with either shRNA targeting
exon 2 of p16
INK4a (p16ex2) or nonsilencing shRNA
(NS) under hU6 and/or hH1 (Figure 2A). These vectors
were transiently transfected into 293T cells and the p16
mRNA expression levels were determined using reverse
transcription-quantitative polymerase chain reaction (Q-
RT-PCR). The mRNA knockdown was achieved when
p16ex2 shRNA was expressed either under the hH1 or
hU6 promoter when compared to control vector.
Furthermore, there was a decrease in shRNA knock-
down when using hH1 promoter, which is consistent
with the previous reports of hH1 being a weaker promo-
ter as compared to hU6 promoter [27]. Double expres-
sion of p16ex2 significantly decreased the p16 mRNA
levels in 293T cells as compared to a single expression
of p16ex2 under either promoter. The additive/double
suppression of p16 mRNA could not be attributed to
nonspecific effects of shRNA silencing since vectors co-
expressing both p16ex2 and control NS showed lower
level of p16 knockdown as compared to vector doubly
expressing p16ex2.
Our next experiment to test the functionality of
pENTRhU6hH1 involved creating stable cell lines that
would allow enough time for any possible shRNA
recombinations known to arise in the targeted cells as a
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Page 3 of 9Figure 2 Successful shRNA/cDNA targeting using designed entry vectors. A) pENTR constructs targeting exon 2 of p16 were transfected
into 293T cells. RNA was isolated 48 hours post transfection and the mRNA expression level was determined using Q-RT-PCR. The average
represents fold gene expression level relative to pENTRhU6hH1 transfected 293T cells (Students t-test; p < 0.01). B) pENTR constructs for CCND1
and/or CCND3 shRNA expression were recombined with plko.puro.DEST. Western blot shows the successful knockdown of CCND1/CCND3 in
Panc1 cells. C) pENTR constructs for p16 shRNA expression were recombined with plko.YFP.DEST. Western blot shows p16 knockdown in H6c7
cells transfected with p16 shRNA constructs. D) pENTR.Cre mediated Cdk4 overexpression in 293T cells transiently transfected with pENTR.Cdk4.
ON. The average represents fold gene expression level relative to control vector cell line f) Luciferase activity downregulation by Cre protein in
stable HeLa cells overexpressing Luc2 mediated by plko.dsRed2.Luc2.ON lentivirus.
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using our system, then the knockdown efficiency would
be greatly impaired. To test this, we chose shRNA
against single targets, cyclin D1 (CCND1) and cyclin D3
(CCND3), which has been previously published [28]. We
created three vectors pENTR.shD1, pENTR.shD3,
pENTR.shD1.shD3 and control vector expressing non-
silencing shRNA, pENTR.shNS (Figure 2A). The result-
ing vectors were recombined with our destination vector
pLKO.puro.DEST and lentiviruses were generated for
transduction into the Panc-1 cell line. Western analysis
on protein lysates from puromycin-selected Panc1 cells
revealed specific knockdown of CCND1 and CCND3
with their respective shRNAs (Figure 2B). In addition,
the Panc1 cell line transduced with shD1_D3 lentivirus
showed significant knockdown of both cyclin D1 and
cyclin D3 proteins with no significant loss of single
shRNA effectiveness (Figure 2B). An upregulation of
CCND3 in shD1 expressing Panc-1 cells was noted. We
observed the same effects previously [28] and attributed
it to a compensatory mechanism. These effects seem to
be alleviated with the co-suppression of CCND3 as
demonstrated in our current results (Figure 2B).
To determine whether our dual shRNA expression
vector can be used to maximize the efficiency of gene
silencing we targeted two different regions in exon 1 of
p16
INK4b mRNA. The experiments were performed on
human pancreatic duct epithelial cell line H6c7 that
expresses very high levels of p16
INK4a due to loss of Rb
secondary to HPV E6/E7 expression [29]. The efficient
knockdown of p16
INK4a in H6c7 cells by shRNA has
presented a major challenge. While we tested 16 differ-
ent shRNAs against p16
INK4a (Additional file 1), none of
the resulting H6c7 stable cell lines has shown greater
than 60% reduction in p16
INK4a levels. Additional tech-
nical difficulty in the specific silencing of p16
INK4a is
that one can only target exon 1, since exons 2 and 3 are
shared with p14
ARF. This limits significantly the available
mRNA sequence for siRNA design. To test if our dual
shRNA expression vector would overcome these pro-
blems, four entry vectors expressing either single or
combination of the most effective shRNAs against
p16
INK4a, shp16AB and shp16CD [30] were recombined
with the plko.YFP.DEST vector (Figure 2C). H6c7 cells
were transduced with the resulting lentiviruses and the
p16 protein levels were assessed by western blotting. As
predicted, the expression of two shRNAs against
p16
INK4a led to a more effective suppression of the
p16
INK4a level than a single shRNA cassette (Figure 2C).
We also tested the actual p16AB and p16CD shRNA
expression under different promoters using Q-RT-PCR
(Additional File 2). While both promoters efficiently
expressed p16AB and p16CD shRNA, there was a lower
siRNA expression under hH1 promoter as compared to
hU6 promoter (Additional File 2). A number of factors
should be considered prior to usage of the hH1 and
hU6 promoters, the first being the potency of the
shRNA used and the second being the cell type. The
hH1 promoter should be employed for intermediate
knockdown, while the hU6 can be used for more potent
applications. Hence, our double shRNA expression vec-
tor can be particularly valuable for dose-dependent stu-
dies where variable expression is required.
Functionality of Cre/lox inducible entry vector
Next, we tested the functionality and efficiency of pENTR.
CMV.ON vector using both transient and stable transfec-
tions. For transient expression testing, cyclin-dependent
kinase 4 (Cdk4) was subcloned into pENTR.CMV.ON vec-
tor. The resulting pENTR.Cdk4.ON and empty control
vector were transfected into 293T cells. As measured by
Q-RT-PCR, Cdk4 was overexpressed (21.73 ± 1.05 fold)
compared to the empty vector control (Figure 2E). Addi-
tionally, co-transfection with the Cre expressing vector,
pENTR.Cre, decreased the Cdk4 mRNA levels to 4.52 ±
0.11 fold relative to the control vector (Figure 2E).
To create stable clones, we constructed vector expres-
sing luciferase protein (pENTR.Luc2.ON) and recom-
bined it with the plko.dsRed2.DEST vector, thus
creating the destination clone plko.dsRed2.Luc2.ON.
Lentiviruses generated using plko.dsRed2.Luc2.ON and
control plko.dsRed2.DEST vectors were used to trans-
duce HeLa cells, which were subsequently sorted for
Red2 fluorescence. Luciferase protein was successfully
overexpressed in HeLa-dsRed2.Luc2.ON cells as mea-
s u r e db yQ - R T - P C R( d a t an o ts h o w n )a n dl u c i f e r a s e
assay (Figure 2F). Transient transfection of pENTR.Cre
into these cells resulted in a significantly decreased luci-
ferase activity (Figure 2F). Taken together these results
demonstrated the functionality of both pENTR.CMV.
ON and plko.dsRed2.DEST vectors.
Functionality of lentiviral destination vectors
W h i l ew es u c c e s s f u l l yd e m o n s t r a t e dt h ee f f i c i e n c yo f
destination vectors plko.puro.DEST, plko.YFP.DEST and
plko.dsRed2.DEST (Figure 2), destination vectors expres-
sing hygromycin (hygro) and green fluorescent protein
(EGFP) remained to be tested.
To test the performance of remaining destination vec-
tors, H6c7 stable cell lines expressing dsRed2 were gen-
erated using lentiviruses from plko.hygro.dsRed2 and
plko.EGFP.dsRed2 vectors. H6c7 cells were selected or
sorted for their respective selectable markers and
changes in red fluorescence were measured by flow
cytometry. The plko.hygro.dsRed2 construct conferred
resistance to hygromycin while plko.EGFP.dsRed2
expressed EGFP (data not shown). Furthermore, all
H6c7 dsRed2 derived cell lines were positive for red
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fully overexpressed using any of our destination vectors
(Figure 3A). The infection of H6c7 dsRed2 derivatives
using Adeno-Cre significantly reduced the expression of
dsRed2 as measured by Red2 fluorescence (Figure 3A).
Viral titer of destination vectors is dependent on the
insert size
It has been demonstrated that lentiviral titer depends
greatly on the insert sequence length due to the packa-
ging capacity of the lentivirus [31,32]. As a result mul-
tiple strategies have been employed over years to
increase the viral titers of pseudotyped lentiviruses
especially for gene therapy applications [33-36]. In
order to fully characterize the efficacy of our expres-
sion system, we tested the viral titer of plko.YFP.DEST
expressing genes of various sizes in 293T cells (Figure
3B). As predicted, our results showed that the viral
titer is proportional to the insert size (Figure 3B).
Although a destination vector with a large cDNA such
as hTERT resulted ultimately in lower lentiviral titer, it
did not impede the ability to efficiently overexpress the
gene in stable H6c7 cell line (Figure 3C). Furthermore,
it has been shown previously that low titer virus
results in unprocessed and defective lentiviruses [35].
However, in our experiments, all YFP positive cells
Figure 3 Functionality and efficacy of lentiviral destination vectors. A) H6c7 cells were transduced with viruses generated using dsRed2
destination expression vectors carrying EGFP or hygro selection markers. Following selection/sorting cells were infected with Adeno-Cre and
subjected to flow cytometry 72 hours post infection. Red fluorescent profiles are compared between infected and non-infected cells. B) Virus
titers of lentiviruses expressing increasing insert size as measured on 293T cells C) hTERT is overexpressed and D) active in H6c7 cell lines stably
transduced with plko.YFP.hTERT.ON lentivirus.
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mined by the hTERT activity assay (Figure 3D). Since
the chance of vector integration event using non-viral
expression system is generally very low, the use of low
titer lentiviruses might still remain a better choice
when creating stable cell lines.
Conclusion
Versatile gene/shRNA expression system is a necessity
in gene functional studies. We have created a modified
gateway lentiviral system for shRNA and Cre/lox induci-
ble gene expression with entry and destination vectors
that are compatible with existing gateway technologies.
These reagents should provide additional choices for
researchers studying many aspects of functional
genomics.
Methods
Vector construction
All detailed maps and sequences of vectors constructed
in this study are available upon request. Construction
strategies, vector maps and restriction enzyme analysis
were performed using Vector
NTI software (Invitrogen,
Carlsbad, CA).
Entry vectors construction
The pENTR.hU6.hH1 was constructed in two steps. In
the first step, XhoI digested hU6 cassette from plko.1-
puro [37] was ligated into XhoI/SalI linearized pENTR-4
vector (Invitrogen, Carlsbad, CA) to construct an inter-
mediate single shRNA expression vector pENTR.hU6.
Then, EcoRI/XhoI digested hH1 cassette from pSUPER-
retro [38] was inserted into EcoRI/XhoIl i n e a r i z e d
pENTR.hU6 vector creating double shRNA expression
vector pENTR.hU6.hH1. We also constructed a second
single shRNA expression vector pENTR-hH1 by remov-
ing hU6 cassette from pENTR.hU6.hH1 with NotI/
EcoRI. Blunt ends were then generated by Klenow reac-
tion and subsequently ligated to make pENTR.hH1.
The pENTR.CMV.ON was constructed by inserting
EcoRV/SnaBI linker cassette from pSicoR-puro-linker-
loxp plasmid containing MCS flanked by loxP sites into
HindIII/SnaBI linearized pENTR.CMV vector. HindIII
site was blunt ended using Klenow reaction. Both inter-
mediate plasmids pSicoR-puro-linker-loxp and pENTR.
CMV vectors were constructed in our laboratory (data
not shown).
Destination vectors
The plko.puro.DEST was constructed by inserting
EcoRV/MluI digested attR1-cmr-ccdb-attR2 cassette
from pTREX-DEST30 (Invitrogen) into ClaI/MluI
digested plko.1-puro vector (ClaI blunt ended with Kle-
now enzyme). The plko.YFP.DEST was constructed by
linearizing plko.YFP (gift from Dr. Linda Penn, Ontario
Cancer Institute, Canada) with AgeI/EcoRI and ligating
AgeI/NheI digestedattR1-cmr-ccdb-attR2 cassette from
pTREX-DEST30. The EcoRIa n dAgeIs i t e sw e r eb l u n t
ended using Klenow enzyme. The plko.dsRed2.DEST was
made by inserting SspI/NsiI dsRed2 cassette from pSU-
PER.dsRed2 (constructed in our laboratory) into the XbaI
(blunt ended)/NsiI digested plko.puro.DEST vector. The
Destination vector plko.hygro.DEST was constructed in
two steps. In the first step, an intermediate plasmid pBS-
hygro was created by subcloning XmnI/SalI hygro cas-
sette from SalI/EcoRV pIND/Hygro (Invitrogen) into
pBluescriptIISK+ (Stratagene). Next, KpnI/SpeIh y g r o
cassette from pBS-hygro was subcloned into plko.puro.
DEST linearized with KpnI/SpeI creating plko.hygro.
DEST vector. To construct plko.EGFP.DEST, the EGFP
PCR fragment was (EGFP: F:5’TAGAATTCTACCGGG-
TAGGGGA3’; R: GGGGGTACCTCATTGGTCT-
TAAAGGTACCGA5’) digested with the KpnI restriction
enzyme at the 3’ end and were then subcloned into the
XcmI/KpnI linearized plko.puro.DEST plasmid.
Subcloning into the entry vectors
The pENTR.Luc.ON was constructed by inserting NheI/
XhoI luciferase fragment from pIND/HygroLuc (Clon-
tech, Mountain View, CA) into AvrII/XhoI linearized
pENTR-CMV-ON. The pENTR-dsRed2-ON was
obtained by ligating dsRed2 fragment (HincII/XhoI) into
HpaI/XhoI linearized pENTR-CMV-ON.
Oligos coding for the various shRNAs were annealed
and cloned into either BglII/HindIII or AgeI/EcoRI-
digested pENTRhU6hH1 as described previously [2]. All
shRNAs used in this study are listed in Additional file 1.
Transfer of cDNA/shRNA cassettes to lentiviral destination
vectors
The constructs were designed to permit subcloning of
shRNA/cDNA cassettes to different expression plat-
forms by Gateway recombination. This involved direct
LR recombination (Invitrogen, San Diego, CA) of the
promoter containing shRNA/cDNA entry vector to any
one of promortless lentiviral destination vectors with
expression of different markers or drug selection genes.
Bacterial strains and transformation
For the construction of entry and destination vectors
containing a toxic ccdB gene competent Escherichia coli
Library Efficiency DB3.1™cells (Invitrogen), were used
for propagation according to the manufacturer’s recom-
mendations. For construction of other vectors and
clones not containing the ccdB gene, SUBCLONING
EFFICIENCY™DH5a competent cells (Invitrogen) were
used for transformation according to the supplier’s
instruction
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HeLa, Panc1 and 293T cells were obtained and cultured
as recommended by the American Type Culture Collec-
tion (Rockville, MD). The Human pancreatic duct
epithelial cell line (H6c7) was cultured as described pre-
viously [29].
Transient transfections and stable cell line generations
For transient transfection assays cells were transfected
using Lipofectamine reagent (Invitrogen, Carlsbad, CA).
For virus preparations, 293T cells were transfected using
BD CalPhos Mammalian Transfection Kit (BD Bios-
ciences). Both assays were performed as per the protocol
provided by the manufacturer.
Virus preparation, transduction and stable cell line
generation
Lentiviruses were prepared by transfecting three plas-
mids into 293T cells as described previously [39]. The
plasmids are pMDLg/pRRE, the vesicular stomatitis
virus (VSV-G) envelope plasmid pCMV-VSG, rev
expressing plasmid pRSV-Rev and destination vectors
containing the self-inactivating LTR. Stocks were stored
frozen at -80°C and tittered on 293T cells.
Stable cell lines were isolated following viral transduc-
tions by either selection in the appropriate antibiotics
for 1-2 weeks (0.5 μg/mL puromycin; 50 μg/mL hygro-
mycin; 100 μg/mL) or by flow sorting using dual-laser
FACSCalibur.
Adenovirus expressing Cre recombinant protein was
purchased from Vector Biolabs (Philadelphia, PA) and
used at 10 moi per cell for 72 hours.
RNA isolation and Q-RT-PCR analysis
RNA isolation and assay techniques used in this paper
were published in our previous work [28]. Primers used
in this study are listed in Additional file 1.
Western analysis
Immunoblotting was performed using whole protein
extracts and probed with the following antibodies
against cyclin D3 (BD Biosciences, San Jose, CA), cyclin
D1 (BD Biosciences), p16
INK4a (Cell Signalling, Boston,
MA) and p14
ARF (NeoMarkers, Freemont, CA), GAPDH
(Abcam, Cambridge, MA), and secondary mouse or rab-
bit conjugated IgG-horseradish peroxidase (Cell
Signalling).
Luciferase and hTERT assay
Luciferase assay was performed using Luciferase Assay
Kit (Promega Madison, WA). The hTERT activity was
measured using TRAPEZE
® RT Telomerase Detection
Kit (Millipore, Billerica, MA). Both kits were used as
recommended by the manufacters protocols.
Flow cytometry
The fluorescent emission intensities of EGFP, YFP and
dsRed2 proteins were measured by FACS analysis using
the FACSCalibur™(BectonDickinson Corp.). Data were
acquired and analyzed using CellQuest™v.3.0.
Additional material
Additional file 1: shRNA sequences and Q-RT-PCR primers used in
this study.
Additional file 2: Figure S1: Comparison of shRNA expression under.
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